Performance is king! The five major performance has skyrocketed, or will it become the next Kelai E

Mondo Finance Updated on 2024-02-20

If you happen to hold these five companies, first of all, congratulations to you, and then they may come out of a round of doubling **. Because they are without exception, their performance is very explosive, and the annual report of the least one is expected to increase by more than 1000%.

Everyone must be clear that after a long period of indiscriminate killing, the valuation has come to a historical low. If the next round of ** will really come out, then the most likely direction is those stocks that are also at the bottom, but have very good performance.

So at the same time, in April every year, it is the time window for annual report disclosure, and at this time, the main force often hypes a wave of annual reports**. For example, Huaxing Venture, which is expected to increase by 160% in its annual report last year, was launched in March, and the stock price rose from more than five yuan to 18 yuan, an increase of more than three times. And the performance of each of these five companies is far more than the original Huaxing. Who are they, like it, come and do it now.

Since its establishment, it has always focused on the research and development, production and sales of two types of integrated circuit special equipment, including non-patterned wafer defect detection equipment series, graphic wafer defect detection equipment series, three-dimensional morphology measurement equipment series, thin film thickness measurement equipment series and other products, which have been applied to the integrated circuit manufacturing production line of 28nm and above process in China. The annual report is expected to increase by 1000%, and the company is the core enterprise of semiconductor testing equipment.

The fourth is Puri Ophthalmology, the company is the largest national ophthalmic chain medical service institution in the domestic non-public ophthalmic medical service industry, its annual report is expected to increase by 1200%, and the company is the second largest ophthalmology enterprise in China.

The third is Ginza shares, mainly engaged in the wholesale and retail business of goods, the main products include all kinds of commodities in the province and the city gradually built a three-dimensional layout of a city and multiple stores, and constantly consolidate the existing competitive advantage. The annual report is expected to increase by 1400%. The company is a well-known large-scale modern retail enterprise group in China.

The second is the new national capital, the company has achieved product sales, service extension and provide high-quality solutions in more than 70 countries around the world, with the increasing customer satisfaction and market recognition, the company's brand value and brand recognition in the international market have gradually become the embodiment of the company's core competitiveness. The annual report is expected to increase by 1500%, and the company is the core enterprise of digital yuan.

The last one is more of a doubling strength, its annual report performance is not only soaring by more than 2700%, and its stock price in the first place has a strong reversal signal, the first chip is highly concentrated, the current stock price is less than ten yuan. As soon as the wind comes, it may usher in the rise of the main rising wave at any time**.

Related Pages